Global biotechs are increasingly turning to CDMOs to accelerate development, reduce operational burden, and access specialised GMP expertise. As advanced therapies grow more complex, partnering with CDMOs offers faster timelines, reliable quality systems, and scalable manufacturing capacity. This shift enables innovators to focus on research while leveraging trusted partners to naviga... https://xellera.livejournal.com/4599.html